Cost-effectiveness of the Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults.

@article{Le2018CosteffectivenessOT,
  title={Cost-effectiveness of the Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults.},
  author={Phuc H Le and Michael B. Rothberg},
  journal={JAMA internal medicine},
  year={2018},
  volume={178 2},
  pages={248-258}
}
Importance The live attenuated herpes zoster vaccine (ZVL) is recommended for immunocompetent adults 60 years or older, but the efficacy wanes with age and over time. A new adjuvanted herpes zoster subunit vaccine (HZ/su) has higher efficacy but might be more expensive. The choice of vaccines depends on their relative values. Objective To assess the cost-effectiveness of HZ/su. Design, Setting, and Participants Markov decision model with transition probabilities based on the US medical… CONTINUE READING

Similar Papers

Loading similar papers…